.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Novartis
Covington
Cantor Fitzgerald
Chinese Patent Office
Healthtrust
Argus Health
Daiichi Sankyo
McKesson
Fish and Richardson

Generated: December 16, 2017

DrugPatentWatch Database Preview

LONSURF Drug Profile

« Back to Dashboard

When do Lonsurf patents expire, and what generic alternatives are available?

Lonsurf is a drug marketed by Taiho Oncology and is included in one NDA. There are three patents protecting this drug.

This drug has forty-nine patent family members in twenty-two countries and four supplementary protection certificates in four countries.

The generic ingredient in LONSURF is tipiracil hydrochloride; trifluridine. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the tipiracil hydrochloride; trifluridine profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-001Sep 22, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-002Sep 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-001Sep 22, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-002Sep 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-001Sep 22, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-001Sep 22, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-002Sep 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-002Sep 22, 2015RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LONSURF

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-001Sep 22, 2015► Subscribe► Subscribe
Taiho OncologyLONSURFtipiracil hydrochloride; trifluridineTABLET;ORAL207981-002Sep 22, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: LONSURF

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,799,783Method of administrating an anticancer drug containing .alpha., .alpha., .alpha.-trifluorothymidine and thymidine phosphorylase inhibitor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LONSURF

Country Document Number Estimated Expiration
Germany60027369► Subscribe
China1297350► Subscribe
LithuaniaPA2017024► Subscribe
China1144587► Subscribe
Australia2006209547► Subscribe
Denmark1080726► Subscribe
Hong Kong1203071► Subscribe
World Intellectual Property Organization (WIPO)2006080327► Subscribe
Australia3192800► Subscribe
Philippines12015502809► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LONSURF

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0889Netherlands► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACIL OF EEN ZOUT VAN TIPIRACIL, ZOALS TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
2017 00036Denmark► SubscribePRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427
2017024Lithuania► SubscribePRODUCT NAME: TRIFLURIDINAS/TIPIRACILAS; REGISTRATION NO/DATE: EU/1/16/1096 20160425
2017000052Germany► SubscribePRODUCT NAME: TRIFLURIDIN IN KOMBINATION MIT TIPIRACIL ODER EINEM SALZ VON TIPIRACIL WIE TIPIRACIL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/16/1096 20160425
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health
Johnson and Johnson
QuintilesIMS
Dow
Novartis
Moodys
Julphar
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot